Island Pharmaceuticals Nets Over $300,000 in R&D Tax Refund

Island Pharmaceuticals Ltd has secured a Research and Development (R&D) tax refund of $386,345 via the Australian Tax Office’s Research and Development (R&D) Tax Incentive for the financial year ending June 2023. The company says the refund is a valuable source of funding for its lead asset, ISLA-101, which is being repurposed for the prevention and treatment of dengue and other mosquito (or vector) borne diseases.